These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 15573104)
1. Pharmaceutical patent challenges--time for reassessment? Glass G Nat Rev Drug Discov; 2004 Dec; 3(12):1057-62. PubMed ID: 15573104 [TBL] [Abstract][Full Text] [Related]
2. How drug life-cycle management patent strategies may impact formulary management. Berger J; Dunn JD; Johnson MM; Karst KR; Shear WC Am J Manag Care; 2016 Oct; 22(16 Suppl):S487-S495. PubMed ID: 28719222 [TBL] [Abstract][Full Text] [Related]
3. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond. Kelly C Food Drug Law J; 2011; 66(3):417-78, iii. PubMed ID: 24505856 [TBL] [Abstract][Full Text] [Related]
4. The Hatch-Waxman Act: encouraging innovation and generic drug competition. Sokal AM; Gerstenblith BA Curr Top Med Chem; 2010; 10(18):1950-9. PubMed ID: 20615183 [TBL] [Abstract][Full Text] [Related]
5. Unsettling drug patent settlements: a framework for presumptive illegality. Carrier MA Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881 [TBL] [Abstract][Full Text] [Related]
6. Patent litigation in India continues to throw up new challenges. Reddy Thikkavarapu P Pharm Pat Anal; 2016 Jul; 5(4):211-6. PubMed ID: 27348790 [TBL] [Abstract][Full Text] [Related]
8. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act. Apel BT Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458 [TBL] [Abstract][Full Text] [Related]
9. Old drugs, new uses: solving a Hatch-Waxman patent predicament. McPhie DC Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929 [No Abstract] [Full Text] [Related]
10. Patent issues in drug development: perspectives of a pharmaceutical scientist-attorney. Melethil S AAPS J; 2005 Oct; 7(3):E723-8. PubMed ID: 16353948 [TBL] [Abstract][Full Text] [Related]
11. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses. Tang WL Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553 [TBL] [Abstract][Full Text] [Related]
12. How would patent reform legislation in the United States impact the pharmaceutical industry? Williams AW Expert Opin Ther Pat; 2015 Feb; 25(2):131-3. PubMed ID: 25387953 [TBL] [Abstract][Full Text] [Related]
13. Teva v. Eisai: what's the real "controversy"? Wang GL Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831 [TBL] [Abstract][Full Text] [Related]
14. Patent quality. Sklan A Pharm Pat Anal; 2014 Jan; 3(1):17-24. PubMed ID: 24354975 [TBL] [Abstract][Full Text] [Related]
15. Innovation strategies for generic drug companies: moving into supergenerics. Ross MS IDrugs; 2010 Apr; 13(4):243-7. PubMed ID: 20373253 [TBL] [Abstract][Full Text] [Related]
16. Obtaining, challenging and enforcing pharmaceutical patents under the America Invents Act. Genieser LH; McCann CE Pharm Pat Anal; 2012 Sep; 1(4):415-26. PubMed ID: 24236880 [TBL] [Abstract][Full Text] [Related]
17. Overview of the Hatch-Waxman Act and its impact on the drug development process. Mossinghoff GJ Food Drug Law J; 1999; 54(2):187-94. PubMed ID: 11758572 [No Abstract] [Full Text] [Related]
18. Drug discovery market exclusivity after KSR: the challenge to pharmaceutical scientists and the US congress. Wolff ME J Pharm Sci; 2011 Aug; 100(8):3044-3054. PubMed ID: 21472728 [TBL] [Abstract][Full Text] [Related]
19. Preliminary injunctions in generic and branded patent litigation. Cohen S; England P Expert Opin Ther Pat; 2013 Sep; 23(9):1083-6. PubMed ID: 23855903 [No Abstract] [Full Text] [Related]
20. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers. Rea TS Food Drug Law J; 1999; 54(2):223-5. PubMed ID: 11759713 [No Abstract] [Full Text] [Related] [Next] [New Search]